600276 恒瑞医药
已收盘 02-02 15:00:00
资讯
新帖
简况
恒瑞医药回购979万股 金额6.46亿元
财中社 · 17:00
恒瑞医药回购979万股 金额6.46亿元
恒瑞医药(600276.SH)重新提交注射用卡瑞利珠单抗的生物制品许可申请获FDA受理
智通财经 · 16:35
恒瑞医药(600276.SH)重新提交注射用卡瑞利珠单抗的生物制品许可申请获FDA受理
江苏恒瑞医药股份有限公司回购A股股份用于员工持股计划
中金财经 · 01-31 09:12
江苏恒瑞医药股份有限公司回购A股股份用于员工持股计划
恒瑞医药(01276)：注射用磷罗拉匹坦帕洛诺司琼(HR20013)的药品上市许可申请获国家药监局受理
智通财经 · 01-30
恒瑞医药(01276)：注射用磷罗拉匹坦帕洛诺司琼(HR20013)的药品上市许可申请获国家药监局受理
185亿美元合作落地！石药集团牵手阿斯利康竞逐减重市场
21世纪经济报道 · 01-30
185亿美元合作落地！石药集团牵手阿斯利康竞逐减重市场
AI重塑医药生产力，为何超六成医药企业拥抱钉钉？
上观新闻 · 01-30
AI重塑医药生产力，为何超六成医药企业拥抱钉钉？
恒瑞医药(01276)获得HRS-7535片临床试验批准通知书
智通财经 · 01-29
恒瑞医药(01276)获得HRS-7535片临床试验批准通知书
恒瑞医药(01276)创新药注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症的上市许可申请获受理
智通财经 · 01-29
恒瑞医药(01276)创新药注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症的上市许可申请获受理
恒瑞医药(01276)1月29日斥资2107.4万元回购37.16万股A股
智通财经 · 01-29
恒瑞医药(01276)1月29日斥资2107.4万元回购37.16万股A股
恒瑞医药(01276)截至1月27日累计回购股份907.37万股
智通财经 · 01-27
恒瑞医药(01276)截至1月27日累计回购股份907.37万股
恒瑞医药(01276)：SHR-1049 注射液获得药物临床试验批准通知书
智通财经 · 01-26
恒瑞医药(01276)：SHR-1049 注射液获得药物临床试验批准通知书
恒瑞医药：二级市场股价受多重因素影响
证券日报 · 01-23
恒瑞医药：二级市场股价受多重因素影响
SHR-7787与阿得贝利单抗同步获批 恒瑞医药推进创新药临床
财中社 · 01-21
SHR-7787与阿得贝利单抗同步获批 恒瑞医药推进创新药临床
21健讯Daily | 恒瑞医药：收到药物临床试验批准通知书；英硅智能：与衡泰生物达成超5亿港元合作
21世纪经济报道 · 01-21
21健讯Daily | 恒瑞医药：收到药物临床试验批准通知书；英硅智能：与衡泰生物达成超5亿港元合作
泡泡玛特，逆市大涨！医药巨头，突传利好
中国基金报 · 01-20
泡泡玛特，逆市大涨！医药巨头，突传利好
花旗集团做空恒瑞医药H股比例升至5.44%，较1月14日的4.81%有所增加
美股速递 · 01-20
花旗集团做空恒瑞医药H股比例升至5.44%，较1月14日的4.81%有所增加
恒瑞医药双款新药获批临床 瞄准晚期实体瘤治疗
财中社 · 01-20
恒瑞医药双款新药获批临床 瞄准晚期实体瘤治疗
恒瑞医药：HRS-2141片获准开展2型糖尿病适应症的临床试验，目前国内外尚无同类药物获批上市
每日经济新闻 · 01-20
恒瑞医药：HRS-2141片获准开展2型糖尿病适应症的临床试验，目前国内外尚无同类药物获批上市
智通AH统计|1月20日
智通财经 · 01-20
智通AH统计|1月20日
FIC/BIC管线突围、BD丰收、港股上市!2026，恒瑞医药站上“爆发点”
智通财经 · 01-18
FIC/BIC管线突围、BD丰收、港股上市!2026，恒瑞医药站上“爆发点”
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":56.49,"timestamp":1770015600000,"preClose":58.16,"halted":0,"volume":60957998,"delay":0,"changeRate":-0.0287,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"已收盘","change":-1.67,"latestTime":"02-02 15:00:00","open":57.76,"high":58.33,"low":56.31,"amount":3482000000,"amplitude":0.0347,"askPrice":56.49,"askSize":1075,"bidPrice":56.48,"bidSize":52,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770082200000},"marketStatusCode":5,"adr":0,"adjPreClose":58.16,"symbolType":"stock","openAndCloseTimeList":[[1769995800000,1770003000000],[1770008400000,1770015600000]],"highLimit":63.98,"lowLimit":52.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":6.3,"roa":"--","peRate":50.204408,"roe":"11.09%","epsLYR":1,"committee":-0.724344,"marketValue":374935000000,"turnoverRate":0.0096,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":67,"timestamp":1770019686002,"preClose":68.45,"halted":0,"volume":4637482,"delay":0,"premium":"+5.39"},"floatMarketCap":360350000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2608854966","title":"恒瑞医药回购979万股 金额6.46亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854966","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608854966?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:00","pubTimestamp":1770022804,"startTime":"0","endTime":"0","summary":"2月2日，恒瑞医药（600276/01276）发布公告，截至2026年1月31日，公司已回购979万股，占总股本的0.15%，回购资金总额为6.46亿元，回购价格区间为56.1元/股至70元/股。2025年前三季度，恒瑞医药实现收入231.88亿元，归母净利润57.51亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638729383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU2543165471.USD","LU2495084118.USD","BK0028","LU0405327494.USD","LU2488822045.USD","BK0183","LU1146622755.USD","LU1997245094.SGD","LU2097828631.EUR","LU2580892789.USD","01276","LU1969619763.USD","LU1328615791.USD","BK0196","LU0405327148.USD","LU1997245177.USD","LU1580142542.USD","LU1023057109.AUD","600276","LU1255011170.USD","LU1820825898.SGD","LU0359201885.HKD","LU1997244956.HKD","LU1064130708.USD","LU1064131003.USD","BK1191","BK0060","BK0239","BK0012","BK0188","LU2289578879.USD","LU2328871848.SGD","LU1655091616.SGD","LU1781817850.SGD","LU2097828714.EUR","LU2148510915.USD","LU0359202008.SGD","LU2097828474.EUR","LU2580892862.HKD","LU2097828805.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2608859435","title":"恒瑞医药(600276.SH)重新提交注射用卡瑞利珠单抗的生物制品许可申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608859435","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608859435?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:35","pubTimestamp":1770021352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，公司收到美国食品药品监督管理局(简称“FDA”)的《确认函》，公司重新提交的注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请(简称“BLA”)获得FDA受理。根据《处方药用户付费法案(PDUFA)》，FDA对注射用卡瑞利珠单抗的目标审评日期为2026年7月23日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","01276","BK0196","LU1023057109.AUD","LU2148510915.USD","600276","LU1655091616.SGD","LU1255011170.USD","LU2097828474.EUR","LU2580892862.HKD","LU1146622755.USD","LU2488822045.USD","LU0359202008.SGD","LU2097828631.EUR","LU0405327148.USD","LU1997245094.SGD","LU1064131003.USD","LU0359201612.USD","BK0188","LU2097828714.EUR","LU2543165471.USD","LU0359201885.HKD","LU2097828805.USD","BK0060","LU1781817850.SGD","LU1997244956.HKD","LU2580892789.USD","LU2495084118.USD","LU1997245177.USD","BK0012","LU1064130708.USD","LU0405327494.USD","BK1191","LU1969619763.USD","LU2097828557.USD","LU1820825898.SGD","LU1580142542.USD","BK0183","LU1328615791.USD","LU2289578879.USD","LU2328871848.SGD","BK0239"],"gpt_icon":0},{"id":"2607078996","title":"江苏恒瑞医药股份有限公司回购A股股份用于员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078996","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607078996?lang=zh_cn&edition=full","pubTime":"2026-01-31 09:12","pubTimestamp":1769821922,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司于2026年1月30日披露了翌日披露报表，报告了其股份变动及回购情况。根据公告，公司于2026年1月30日通过上海证券交易所交易系统以集中竞价交易方式回购了343,100股A股股份，占公司总股本的约0.0054%。此次回购的每股最高价格为人民币58.21元，每股最低价格为人民币58.12元，支付的总金额为人民币19,959,865元。 公告明确，本次回购的股份将全部用于公司A股员工持股计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260131/31989089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","LU1255011170.USD","159982","LU1655091616.SGD","LU1781817850.SGD","LU0405327148.USD","LU2580892862.HKD","LU0359202008.SGD","LU2097828805.USD","LU2328871848.SGD","LU2097828557.USD","399300","LU0359201885.HKD","LU1969619763.USD","LU1064130708.USD","LU2097828631.EUR","LU2488822045.USD","LU0359201612.USD","LU2097828474.EUR","LU1820825898.SGD","LU2289578879.USD","LU1997245177.USD","BK0196","BK0028","LU1997244956.HKD","BK0060","BK0188","600276","LU1146622755.USD","BK1191","LU2580892789.USD","LU1064131003.USD","LU1580142542.USD","BK0012","LU1023057109.AUD","01276","LU2543165471.USD","LU2148510915.USD","LU2495084118.USD","LU1997245094.SGD","LU1328615791.USD","BK0183","LU0405327494.USD","LU2097828714.EUR"],"gpt_icon":0},{"id":"2607142870","title":"恒瑞医药(01276)：注射用磷罗拉匹坦帕洛诺司琼(HR20013)的药品上市许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2607142870","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607142870?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:18","pubTimestamp":1769771932,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司注射用磷罗拉匹坦帕洛诺司琼的药品上市许可申请获国家药监局受理。此次申报新适应症，是基于一项评价注射用磷罗拉匹坦帕洛诺司琼用于预防中度致吐性抗肿瘤药物引起恶心呕吐的有效性和安全性的多中心、随机、双盲、阳性对照的Ⅲ期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1997245094.SGD","LU1969619763.USD","LU2289578879.USD","LU2148510915.USD","LU2580892789.USD","BK1191","LU0359201612.USD","LU2580892862.HKD","LU2097828805.USD","LU1580142542.USD","LU1328615791.USD","LU2097828474.EUR","LU1997244956.HKD","LU1997245177.USD","LU2097828557.USD","BK0028","LU1146622755.USD","BK0012","BK0188","LU0359202008.SGD","LU0359201885.HKD","LU2097828714.EUR","LU1064130708.USD","LU0405327494.USD","LU0405327148.USD","LU2488822045.USD","LU1655091616.SGD","LU1064131003.USD","BK0196","LU1781817850.SGD","LU2097828631.EUR","01276","600276","BK0183","LU2328871848.SGD","LU1023057109.AUD","LU1255011170.USD","LU2543165471.USD","BK0060","LU1820825898.SGD","LU2495084118.USD"],"gpt_icon":0},{"id":"2607093966","title":"185亿美元合作落地！石药集团牵手阿斯利康竞逐减重市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2607093966","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607093966?lang=zh_cn&edition=full","pubTime":"2026-01-30 13:52","pubTimestamp":1769752320,"startTime":"0","endTime":"0","summary":"1月30日开盘前，石药集团（1093.HK）公告称，已与阿斯利康签署战略研发合作与授权协议。双方将依托石药集团专有的缓释给药技术平台及多肽药物AI发现平台，联合开发创新长效多肽药物。本次合 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260130/c674429187.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260130/c674429187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1580142542.USD","000963","BK0239","LU1064131003.USD","BK0060","LU1655091616.SGD","LU2097828631.EUR","LU2097828805.USD","LU2148510915.USD","BK0183","LU1820825898.SGD","LU1146622755.USD","LU2097828474.EUR","600276","BK0209","LU0405327494.USD","LU1255011170.USD","LU2495084118.USD","LU1328615791.USD","LU2580892862.HKD","BK0188","LU2328871848.SGD","LU1064130708.USD","BK0132","LU1969619763.USD","LU1997244956.HKD","LU2580892789.USD","LU1781817850.SGD","BK0196","BK0187","LU0405327148.USD","BK0175","LU1997245094.SGD","LU2097828557.USD","LU2488822045.USD","BK0028","LU2097828714.EUR","LU2289578879.USD","BK0012","LU1997245177.USD"],"gpt_icon":0},{"id":"2607025472","title":"AI重塑医药生产力，为何超六成医药企业拥抱钉钉？","url":"https://stock-news.laohu8.com/highlight/detail?id=2607025472","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607025472?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:43","pubTimestamp":1769737380,"startTime":"0","endTime":"0","summary":"以“AI重塑医药生产力”为主题的2026医药钉峰会日前在沪召开，共探人工智能技术如何驱动赋能医药行业。AI自动完成数据抓取、分析与预警，让人人皆可成为开发者，大幅提升了业务响应的敏捷性。此外，AI正成为药企全球化协同的基石。AI不再是遥远的技术概念，而是已经成为医药行业提质、增效、创新的核心驱动要素。随着AI技术产品持续完善、行业生态日益繁荣，一场以人工智能为核心的医药生产力革命，正从蓝图加速照进现实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0819121731.USD","LU0708995153.HKD","LU0235996351.USD","BK1588","LU2778985437.USD","LU0823041008.USD","LU0823413660.USD","LU1051768304.USD","LU0264606111.USD","LU0320764599.SGD","LU0441854154.USD","BK1521","LU0543330566.HKD","LU0873338254.USD","LU0611395673.USD","LU0979878070.USD","LU0675040207.SGD","LU0516423174.USD","LU0127658192.USD","LU1719994722.HKD","LU0054237671.USD","SG9999004220.SGD","LU1720050803.USD","LU0329678337.USD","LU2328871848.SGD","LU0856984785.SGD","LU1048484197.HKD","LU0455707207.USD","SG9999000459.SGD","LU0577902454.USD","LU0784639295.USD","BK1615","LU2242644610.SGD","LU1831875114.USD","LU0348735423.USD","BK1517","LU0762540952.USD","02157","LU0417516738.SGD","LU0823039010.USD","LU2399975544.HKD","LU0577902538.SGD","LU0588545730.USD","LU3063872942.SGD","LU0828237510.HKD","LU1642822792.SGD","LU0143863198.USD","LU0181495838.USD","LU1880383440.USD","BK1608","LU0130518102.USD","BK1583","LU0054450605.USD","BK1610","LU0359201885.HKD","01276","LU0163747925.USD","LU0541502299.USD","LU0314109678.HKD","LU1282651048.USD","LU0449515922.USD","LU0865486749.SGD","LU0868486357.SGD","IE00B3M56506.USD","LU1880398471.USD","LU0831103253.SGD","LU1504937902.USD","LU1044876610.USD","LU0345776255.USD","LU1242518931.SGD","LU1769817179.HKD","LU0011963245.USD","LU0320764755.SGD","LU1282649810.SGD","LU0823397103.USD","LU2125910500.SGD","LU0327786744.USD","SG9999001093.SGD","LU0348788117.USD","LU0348827113.USD","LU1969619763.USD","LU1224444064.USD","LU2045819591.USD","LU0594300419.USD","LU1196710864.SGD","LU1956131251.USD","LU0287142896.SGD","LU0214875030.USD","89988","LU0251144936.SGD","LU1044875133.USD","LU2097828714.EUR","LU1188198961.HKD","LU0821914370.USD","LU0708995583.HKD","IE00B0JY6N72.USD","LU1316542783.SGD","LU1808992512.USD","LU0469268626.HKD","LU0106959298.USD","LU0823413587.USD","LU0164872284.USD","SG9999000327.SGD","LU0320764243.SGD","LU0588545904.SGD","06127","IE0032431581.USD","IE00B0169N27.USD","LU0890818403.SGD","LU0862451837.USD","LU2152927971.USD","LU0348783662.USD","LU0607220059.USD","BK1591","LU0164865239.USD","BK1501","LU0502904849.HKD","LU0572940350.SGD","LU1044874839.SGD","LU1481107354.HKD","LU0128522744.USD","LU1048596156.SGD","SGXZ90724238.SGD","LU1770036033.HKD","LU0499858602.USD","LU0210526637.USD","LU0128522157.USD","LU0516422366.SGD","601607","LU0886674414.USD","LU0029874905.USD","LU0823038988.USD","LU0417516571.SGD","IE0003895053.USD","LU0048580855.USD","LU1993786604.SGD","LU1282649141.HKD","LU0456846285.SGD","LU1023057109.AUD","09988","LU0871576103.HKD","LU1048588211.SGD","LU2097828631.EUR","LU0608807946.USD","LU1328615791.USD","LU0828237940.HKD","LU0051755006.USD","LU1794554557.SGD","LU1655091459.SGD","SG9999006514.SGD","LU0254981946.USD","LU0516422952.EUR","LU0348805143.USD","BK1142","BABA","LU0315178854.USD","LU1720051108.HKD","LU0449509016.USD","LU0737861699.HKD","LU0531971595.HKD","02607","LU1439103000.SGD","LU0831093199.SGD","LU0456827905.SGD","IE00B5MMRT66.SGD","LU0672654166.SGD","LU0516423091.SGD","LU0737861772.HKD","LU1981816686.USD","LU0231483743.USD","LU1115378108.SGD","BK1586","LU0307460666.USD","IE00B543WZ88.USD","LU1303224171.USD","LU2293587155.HKD","LU0577902611.USD","LU2097828474.EUR","SG9999002828.SGD","LU0540923850.HKD","LU0651946864.USD","BK1589","SG9999002463.SGD","LU0132412106.USD","LU1323998911.USD","IE00BZ08YR35.GBP","LU0823040885.USD","LU0762542818.HKD","BK1249","LU2449936058.SGD","000538","LU1051769294.HKD","LU1807302812.USD","LU1960683339.HKD","HK0000320223.HKD","LU0348783233.USD","LU0819123356.HKD","SG9999001689.USD","IE00BPRC5H50.USD","LU0164880469.USD","LU0048597586.USD","LU1211504680.USD","LU0700851271.USD","LU0169518387.USD","LU0359201612.USD","LU0608807433.USD","LU1201861165.SGD","LU0516422440.USD","SG9999001051.SGD","LU0173614495.USD","LU0149721374.USD","LU0499858438.USD","LU0293314216.USD","LU0463099449.HKD","LU2097829019.USD","BK1161","LU2087589342.USD","LU0593848301.USD","LU2476274720.SGD","LU1880398554.USD","LU0359202008.SGD","IE00BMPRXN33.USD","SG9999006597.SGD","HK0000320264.USD","LU0648948544.HKD","LU0117844026.USD","LU0096374516.USD","LU1548497426.USD","BK1618","LU1720051017.SGD","LU0029875118.USD","BK1515","LU0589944569.HKD","LU1961090484.USD","LU0228659784.USD","LU1282651121.HKD","LU2257852520.SGD","IE0034224299.USD","LU0348825331.USD","LU0577902371.SGD","LU0117841782.USD","LU0630378429.USD","LU0049853897.USD","LU0823397285.USD","LU0197773160.USD","LU0384037296.USD","LU1515016050.SGD","SG9999001226.SGD","IE00BZ08YT58.USD","LU0196878994.USD","LU0143863784.USD","LU0345775950.USD","LU0228367735.SGD","LU0052750758.USD","SG9999002562.SGD","LU0084288322.USD","LU1242518857.USD","LU0165289439.USD","LU0197773673.USD","01801","600276","LU0634319403.HKD","LU1366334578.USD","LU0244354667.USD","LU0259732245.USD","IE00BZ08YS42.EUR","IE00BMPRXR70.SGD","LU0149534421.HKD","LU0328353924.USD","LU0642271901.SGD","BK1574","LU0261950983.USD","BK1584","LU1224709979.USD","HK0000306701.USD","SHPMY","LU0588545490.SGD","LU0326950275.SGD","LU0640798160.USD","LU0762541174.USD","LU1770034418.SGD","HBBD.SI","LU0791591158.USD","LU0488056044.USD","LU0047713382.USD","LU2488822045.USD","SG9999014674.SGD","LU0862451753.SGD","LU0543330483.HKD","BK1575","LU0651947912.USD","LU0791590937.USD","LU0588546209.SGD","LU0210527791.USD","LU0211977185.USD","LU0048388663.USD","LU0431992006.USD","LU1568876335.HKD","SG9999001903.USD","LU0823426308.USD","LU0630378692.HKD","LU0261947096.USD","LU1880383366.USD","LU0561508036.HKD","LU0140636845.USD","LU1251922891.USD","LU1769817096.USD","LU1810669033.SGD","LU0417516902.SGD","LU0039217434.USD","LU0823426480.USD","LU0370786039.SGD","LU0061477393.USD","LU0898667661.SGD","LU2125910849.SGD","LU0531970944.HKD","LU0594300179.USD","LU0329678170.USD","LU1366334651.USD","LU0348784397.USD","LU0572939691.SGD","HK0000306685.HKD","LU1868837565.USD","LU2097828805.USD","LU2039709279.SGD","LU2097828557.USD","LU0572944931.SGD","LU1328277881.USD","LU1568876251.USD","HK0000165453.HKD","LU1688375341.USD","LU0106259558.USD","LU0541501648.USD","LU0229945570.USD","LU1282649067.USD","LU2357305700.SGD","LU0605514214.HKD","603127","IE0008368304.USD","LU0072462343.USD","LU0130103400.USD","ALBmain","LU0106252389.USD","LU0043850808.USD","LU2476274308.USD","LU1813983027.USD","LU1868838027.USD","LU0650527681.SGD","BK1502","LU0315179316.USD","LU0477156797.USD","LU0396098781.USD","LU0577902298.EUR","LU0648000940.SGD"],"gpt_icon":1},{"id":"2607057702","title":"恒瑞医药(01276)获得HRS-7535片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607057702","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607057702?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:20","pubTimestamp":1769678459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于 HRS-7535 片的《药物临床试验批准通知书》，将于近期开展临床试验。临床前数据显示 HRS-7535 可显著改善动物慢性肾脏病症状。全球范围内尚无口服小分子 GLP-1R 激动剂上市。截至目前，HRS-7535 片相关项目累计研发投入约 36,940 万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1781817850.SGD","LU2148510915.USD","LU1580142542.USD","LU2543165471.USD","BK1191","BK0196","LU1655091616.SGD","LU1997245094.SGD","01276","LU2097828631.EUR","LU2488822045.USD","LU1820825898.SGD","BK0060","LU2097828714.EUR","LU2289578879.USD","BK0188","LU1146622755.USD","LU2580892789.USD","LU1969619763.USD","LU2328871848.SGD","LU2495084118.USD","BK0028","LU1997244956.HKD","LU2097828557.USD","LU0405327494.USD","LU1328615791.USD","BK0012","LU0359201885.HKD","LU0405327148.USD","LU2097828805.USD","600276","BK0183","LU1023057109.AUD","LU1255011170.USD","LU2580892862.HKD","BK0239","LU0359202008.SGD","LU1064130708.USD","LU1997245177.USD","LU0359201612.USD","LU2097828474.EUR","LU1064131003.USD"],"gpt_icon":0},{"id":"2607024507","title":"恒瑞医药(01276)创新药注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症的上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2607024507","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607024507?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:17","pubTimestamp":1769678270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司及子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司创新药注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症的上市许可申请获受理。研究期中分析结果表明，与单纯 TACE 治疗相比，卡瑞利珠单抗联合甲磺酸阿帕替尼和 TACE 组 BIRC 评估的 PFS 达到了显著有临床意义的改善，且已观察到 OS 获益趋势。该联合疗法有望成为不可切除肝细胞癌患者的临床治疗新选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","159992","BK0239","LU1997245094.SGD","BK0060","LU1023057109.AUD","LU0359201612.USD","BK1191","06978","LU2097828631.EUR","600276","LU1328615791.USD","LU1064131003.USD","LU2580892789.USD","BK1574","LU1064130708.USD","LU2328871848.SGD","LU1655091616.SGD","BK0183","LU2488822045.USD","LU2097828805.USD","LU1146622755.USD","BK1161","LU2097828557.USD","LU2543165471.USD","LU2289578879.USD","BK0012","LU1580142542.USD","LU0359202008.SGD","LU1997244956.HKD","LU2495084118.USD","01276","LU2097828714.EUR","LU0405327148.USD","LU1969619763.USD","LU0359201885.HKD","LU1997245177.USD","LU1781817850.SGD","LU2148510915.USD","BK0028","BK0196","LU1820825898.SGD","LU2580892862.HKD","LU0405327494.USD","LU2097828474.EUR","LU1255011170.USD"],"gpt_icon":0},{"id":"2607907701","title":"恒瑞医药(01276)1月29日斥资2107.4万元回购37.16万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607907701","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607907701?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:29","pubTimestamp":1769675370,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年1月29日，该公司斥资人民币2107.4万元回购37.16万股A股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU1655091616.SGD","LU2495084118.USD","LU2148510915.USD","LU1969619763.USD","LU2580892862.HKD","LU2580892789.USD","LU0405327494.USD","LU1328615791.USD","LU1997244956.HKD","LU2289578879.USD","LU0405327148.USD","LU1064131003.USD","BK1191","LU1064130708.USD","BK0060","LU1997245094.SGD","LU2543165471.USD","LU2097828714.EUR","BK0188","LU1781817850.SGD","LU0359201612.USD","LU0359201885.HKD","LU1580142542.USD","LU1997245177.USD","BK0196","LU1255011170.USD","LU2097828805.USD","BK0239","399300","LU1146622755.USD","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","BK0183","BK0028","LU1820825898.SGD","BK0012","159982","LU2097828474.EUR","01276","LU2328871848.SGD","LU0359202008.SGD","600276"],"gpt_icon":0},{"id":"2606207472","title":"恒瑞医药(01276)截至1月27日累计回购股份907.37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606207472","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606207472?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:46","pubTimestamp":1769507189,"startTime":"0","endTime":"0","summary":"回购期限为自董事会审议通过回购股份方案之日起12个月以内。截至2026年1月27日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份907.37万股，已回购股份占公司总股本的比例为0.14%，购买的最高价为人民币70.00元/股，最低价为人民币57.20元/股，已支付的总金额为人民币6.05亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","600276","LU1146622755.USD","BK0196","BK0012","LU2097828631.EUR","01276","LU0359201612.USD","BK0188","LU1328615791.USD","LU2328871848.SGD","LU2097828714.EUR","LU0359202008.SGD","LU1655091616.SGD","LU1023057109.AUD","LU2580892862.HKD","BK0239","LU2097828557.USD","BK1191","LU1580142542.USD","LU1820825898.SGD","BK0060","LU1064131003.USD","LU2495084118.USD","LU2148510915.USD","LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","LU2543165471.USD","LU1781817850.SGD","LU2097828474.EUR","LU1997244956.HKD","LU2580892789.USD","LU2289578879.USD","LU0405327148.USD","LU1255011170.USD","LU1997245094.SGD","BK0028","LU1064130708.USD","LU0359201885.HKD","LU1997245177.USD","BK0183"],"gpt_icon":0},{"id":"2606213660","title":"恒瑞医药(01276)：SHR-1049 注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2606213660","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606213660?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:58","pubTimestamp":1769417930,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，公司收到国家药品监督管理局核准签发关于 SHR-1049 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-1049 注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-1049 注射液相关项目累计研发投入约为 2600 万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245094.SGD","LU1781817850.SGD","LU2097828557.USD","600276","LU2097828474.EUR","BK0183","01276","LU1255011170.USD","LU1997244956.HKD","LU1655091616.SGD","LU2097828805.USD","BK0028","LU1064131003.USD","LU2580892862.HKD","LU2495084118.USD","LU1820825898.SGD","LU1997245177.USD","LU1328615791.USD","BK0188","BK0196","LU2097828714.EUR","LU1064130708.USD","BK0060","BK1191","LU0359202008.SGD","LU0405327148.USD","LU1023057109.AUD","LU2148510915.USD","LU0359201885.HKD","LU2328871848.SGD","LU2580892789.USD","BK0012","LU0405327494.USD","LU2488822045.USD","LU2097828631.EUR","LU2543165471.USD","LU2289578879.USD","LU1969619763.USD","LU1580142542.USD","LU1146622755.USD","LU0359201612.USD","BK0239"],"gpt_icon":0},{"id":"2605471277","title":"恒瑞医药：二级市场股价受多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2605471277","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605471277?lang=zh_cn&edition=full","pubTime":"2026-01-23 19:12","pubTimestamp":1769166728,"startTime":"0","endTime":"0","summary":"证券日报网讯1月23日，恒瑞医药在互动平台回答投资者提问时表示，二级市场股价受宏观经济、市场情绪等多重因素影响。公司严格按照交易所相关规定，根据已披露的股份回购方案进行股份回购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233629080347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2289578879.USD","BK0060","LU1781817850.SGD","BK0183","BK1191","LU1655091616.SGD","LU1997245094.SGD","LU2495084118.USD","LU1820825898.SGD","LU1969619763.USD","LU1328615791.USD","LU1064131003.USD","LU1580142542.USD","LU1997244956.HKD","01276","LU1146622755.USD","LU0359201885.HKD","LU2543165471.USD","BK0028","LU2097828474.EUR","LU1255011170.USD","LU1064130708.USD","LU0405327494.USD","LU2488822045.USD","LU2328871848.SGD","BK0239","LU2148510915.USD","LU2097828805.USD","LU2580892789.USD","BK0188","600276","LU2097828557.USD","BK0012","LU2097828714.EUR","BK0196","LU2580892862.HKD","LU2097828631.EUR","LU0359201612.USD","LU1023057109.AUD","LU0359202008.SGD","LU1997245177.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2605172663","title":"SHR-7787与阿得贝利单抗同步获批 恒瑞医药推进创新药临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2605172663","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605172663?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:55","pubTimestamp":1768985708,"startTime":"0","endTime":"0","summary":"1月21日，恒瑞医药（600276/01276）发布公告，公司子公司上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发的SHR-7787注射液和阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-7787注射液为1类治疗用生物制品，相关项目累计研发投入约为5410万元（未经审计）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601213626104786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","BK1161","159992","600276","BK0028","01276","BK1574","LU2097828805.USD","LU1580142542.USD","06978","LU1820825898.SGD","BK0196","LU2488822045.USD","LU0359201885.HKD","LU1255011170.USD","LU1064130708.USD","LU1146622755.USD","LU1997245177.USD","LU2495084118.USD","BK0012","LU1969619763.USD","LU0405327494.USD","LU2289578879.USD","LU2543165471.USD","LU1781817850.SGD","LU1328615791.USD","LU1997245094.SGD","LU2097828557.USD","LU1023057109.AUD","LU0359202008.SGD","LU1997244956.HKD","BK0183","LU1655091616.SGD","BK1191","LU2097828474.EUR","LU2148510915.USD","BK0060","LU0359201612.USD","LU2328871848.SGD","LU2580892789.USD","BK0239","LU0405327148.USD","LU2580892862.HKD","LU2097828714.EUR","BK0188","LU2097828631.EUR"],"gpt_icon":0},{"id":"2605122476","title":"21健讯Daily | 恒瑞医药：收到药物临床试验批准通知书；英硅智能：与衡泰生物达成超5亿港元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2605122476","media":"21世纪经济报道","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605122476?lang=zh_cn&edition=full","pubTime":"2026-01-21 12:02","pubTimestamp":1768968125,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向“手术机器人”“远程手术”等辅助操作全国统一价格立项1月20日，据国家医保局官网，医疗技术进步离不开医疗器械的发展，医疗技术进步史也是一部医疗器械的发展史。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601213625851264.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601213625851264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU1997245094.SGD","LU1969619763.USD","LU2289578879.USD","LU2148510915.USD","LU2580892789.USD","BK1191","LU0359201612.USD","LU2580892862.HKD","LU2097828805.USD","LU1580142542.USD","LU1328615791.USD","LU2097828474.EUR","LU1997244956.HKD","LU1997245177.USD","LU2097828557.USD","BK0028","LU1146622755.USD","BK0012","BK0188","LU0359202008.SGD","LU0359201885.HKD","LU2097828714.EUR","LU1064130708.USD","LU0405327494.USD","LU0405327148.USD","LU2488822045.USD","LU1655091616.SGD","LU1064131003.USD","BK0196","LU1781817850.SGD","LU2097828631.EUR","01276","600276","BK0183","LU2328871848.SGD","LU1023057109.AUD","LU1255011170.USD","LU2543165471.USD","BK0060","LU1820825898.SGD","LU2495084118.USD"],"gpt_icon":0},{"id":"2604659192","title":"泡泡玛特，逆市大涨！医药巨头，突传利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2604659192","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604659192?lang=zh_cn&edition=full","pubTime":"2026-01-20 18:53","pubTimestamp":1768906407,"startTime":"0","endTime":"0","summary":"涨幅方面，泡泡玛特涨9.07%，中国人寿涨4.31%，华润置地涨3.71%，领涨蓝筹。“股份回购+大摩唱多”泡泡玛特逆市大涨超9%！1月19日，泡泡玛特披露，当天通过香港联交所购回140万股普通股，每股购回价介于177.7港元至181.2港元，涉及金额达2.51亿港元。泡泡玛特公告称，公司董事会于2025年5月27日审议通过，授权公司进行总数为1.34亿股公司股份回购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120190121a440c16a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120190121a440c16a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","BK1161","600276","BK1515","LU0348767384.USD","BK1224","LU0231483743.USD","LU0345776255.USD","01276","BK1574","LU0499858438.USD","LU0593848301.USD","LU1770036033.HKD","LU0307460666.USD","LU0359201885.HKD","LU0611395673.USD","LU0531971595.HKD","LU0164880469.USD","IE0034224299.USD","LU0348766576.USD","LU0823426308.USD","LU0871576103.HKD","SGXZ86797644.SGD","SG9999002950.SGD","LU0211977185.USD","LU0499858602.USD","09992","LU2543165471.USD","SGXZ62798434.SGD","LU0149721374.USD","LU0327786744.USD","LU1481107354.HKD","LU0823426480.USD","LU1023057109.AUD","LU0359202008.SGD","SG9999001069.SGD","LU0572944931.SGD","PMRTY","LU0039217434.USD","LU0164865239.USD","LU0359201612.USD","LU0345775950.USD"],"gpt_icon":1},{"id":"1144446914","title":"花旗集团做空恒瑞医药H股比例升至5.44%，较1月14日的4.81%有所增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1144446914","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144446914?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:28","pubTimestamp":1768901325,"startTime":"0","endTime":"0","summary":"根据香港交易所披露的数据显示，花旗集团对恒瑞医药H股的做空仓位在1月14日出现显著上升。具体而言，其做空比例从之前的4.81%增加至5.44%，增幅明显。\n做空仓位的上升通常反映市场参与者对相关股票短期走势持谨慎或看空态度。此次花旗集团做空比例的提升，可能引发投资者对恒瑞医药H股后市表现的关注。\n恒瑞医药作为国内医药行业的重要企业，其股价波动及市场情绪变化一直备受瞩目。做空比例的变化亦是市场多空力量博弈的一个侧面体现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","BK0188","LU2097828474.EUR","BK0012","600276","BK0196","LU2328871848.SGD","LU1997245094.SGD","LU1580142542.USD","LU1997244956.HKD","LU1655091616.SGD","LU1969619763.USD","LU2289578879.USD","LU0405327494.USD","LU1820825898.SGD","LU1255011170.USD","LU2488822045.USD","LU1997245177.USD","LU1781817850.SGD","LU2097828631.EUR","LU1064131003.USD","BK0060","LU1064130708.USD","LU2580892789.USD","LU1146622755.USD","BK0183","LU2097828714.EUR","LU1328615791.USD","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","LU2097828557.USD","BK0028","BK0239","LU2580892862.HKD"],"gpt_icon":0},{"id":"2604819546","title":"恒瑞医药双款新药获批临床 瞄准晚期实体瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2604819546","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604819546?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:09","pubTimestamp":1768900164,"startTime":"0","endTime":"0","summary":"1月20日，恒瑞医药（600276/01276）发布公告，近日公司及子公司收到国家药品监督管理局核准签发的关于注射用SHR-9839（sc）和HRS-4642注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-9839为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，相关项目累计研发投入约为9390万元（未经审计）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624743863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU2097828557.USD","LU0359201612.USD","LU2097828714.EUR","LU2580892862.HKD","LU1997244956.HKD","BK1191","LU2097828631.EUR","LU2097828474.EUR","01276","LU1146622755.USD","LU2488822045.USD","BK0012","LU2580892789.USD","LU1064131003.USD","LU1820825898.SGD","LU2148510915.USD","LU1997245094.SGD","BK0183","LU1255011170.USD","LU1023057109.AUD","LU2543165471.USD","BK0028","BK0188","BK0060","LU1969619763.USD","LU1781817850.SGD","LU1064130708.USD","LU2328871848.SGD","LU1580142542.USD","LU1997245177.USD","600276","LU1328615791.USD","LU0359201885.HKD","LU2289578879.USD","LU0359202008.SGD","LU1655091616.SGD","LU2097828805.USD","LU0405327148.USD","BK0196","LU2495084118.USD","LU0405327494.USD"],"gpt_icon":0},{"id":"2604219587","title":"恒瑞医药：HRS-2141片获准开展2型糖尿病适应症的临床试验，目前国内外尚无同类药物获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2604219587","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604219587?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:57","pubTimestamp":1768899434,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月20日，恒瑞医药(600276.SH)公告称，子公司山东盛迪医药有限公司收到国家药监局核准签发关于HRS-2141片（Ⅰ）、（Ⅱ）的《药物临床试验批准通知书》，同意开展2型糖尿病适应症的临床试验。该药物为固定剂量复方制剂，通过药理机制互补协同降血糖，目前国内外尚无同类药物获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203624727059.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624727059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828805.USD","LU0359201885.HKD","LU1580142542.USD","LU1820825898.SGD","LU2488822045.USD","LU1023057109.AUD","LU1969619763.USD","LU1997244956.HKD","LU2097828557.USD","LU1781817850.SGD","LU1255011170.USD","01276","BK0060","BK0188","LU1655091616.SGD","LU2148510915.USD","LU0405327494.USD","BK0239","BK0028","LU2097828714.EUR","LU2580892789.USD","LU2097828474.EUR","LU2328871848.SGD","LU1064130708.USD","BK0183","LU2289578879.USD","LU2543165471.USD","LU2097828631.EUR","LU1328615791.USD","BK1191","BK0196","LU1997245177.USD","LU1064131003.USD","BK0012","LU0359201612.USD","LU2580892862.HKD","600276","LU2495084118.USD","LU1146622755.USD","LU0405327148.USD","LU1997245094.SGD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2604198556","title":"智通AH统计|1月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2604198556","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604198556?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:15","pubTimestamp":1768896906,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止1月20日收盘，东北电气、浙江世宝、钧达股份分列AH溢价率前三位，溢价率分别为815.25%、386.24%、369.87%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-12.69%、-0.92%、-0.12%。其中钧达股份、金风科技、三花智控的偏离值位居前三，分别为138.55%、35.44%、18.71%；另外，东北电气、晨鸣纸业、中国人寿的偏离值位居后三，分别为-39.75%、-27.60%、-19.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999012744.USD","HK0000306701.USD","LU1115378108.SGD","BK1237","IE00BMCWC346.EUR","LU0737861699.HKD","LU0708995583.HKD","LU1023057109.AUD","LU1188198961.HKD","LU0348816934.USD","LU1769817179.HKD","BK1521","LU0320764599.SGD","LU2476274308.USD","LU0456846285.SGD","LU2097828805.USD","LU0516423174.USD","BK1116","LU0061477393.USD","LU0417516902.SGD","BK1231","SG9999014674.SGD","SG9999012728.SGD","IE0008368742.USD","IE00BVYPNQ40.USD","LU2097828631.EUR","LU1046422090.SGD","LU0211977185.USD","LU1813983027.USD","BK1522","LU2399975544.HKD","LU0328353924.USD","CIHKY","IE00B29SXG58.USD","LU0540923850.HKD","BK1148","IE00B031HY20.USD","LU0326950275.SGD","BK1149","LU0106959298.USD","LU0431992006.USD","LU0516422366.SGD","LU0862451753.SGD","LU1719994722.HKD","LU0266512127.USD","LU2039709279.SGD","LU2097828557.USD","BK1560","600276","LU0561508036.HKD","IE00BZ08YS42.EUR","BK1161","LU0828237510.HKD","BK1610","LU1770034418.SGD","LU0117841782.USD","03968","LU0228367735.SGD","LU0067412154.USD","LU1282649067.USD","01812","LU0345780521.USD","BK1526","LU0359201885.HKD","LU0469268626.HKD","LU1481107354.HKD","IE0008369823.USD","BK1214","LU0417516738.SGD","SG9999012736.USD","IE0032431581.USD","BK1507","LU0048580855.USD","002703","BK1506","BK1574","LU0039217434.USD","BK1191","IE00BYV24P56.USD","LU0049853897.USD","LU0348825331.USD","LU0868486357.SGD","IE00B031J352.USD","BK1190","LU0516422440.USD","BK1562","BK1205","LU0359201612.USD","LU0072913022.USD","IE00B3M56506.USD","SG9999004220.SGD","LU1366334578.USD","BK1503","BK1141","159982","LU0634319403.HKD","LU0384037296.USD","LU1785774172.SGD","SG9999002828.SGD","LU0229945570.USD","LU1282649141.HKD","BK1523","600036","002050","IE00BVYPNP33.GBP","LU0823426308.USD","LU1961090484.USD","SG9999001069.SGD","SGXZ90724238.SGD","300750","BK1513","BK1223","BK1576","BK1166","BK1183","LU2125910500.SGD","BK1583","002865","LU0173614495.USD","01276","02628","LU0370786039.SGD","LU0456854461.SGD","LU0791590937.USD","LU1242518931.SGD","BK1144","BK1181","LU0572944931.SGD","LU1808992512.USD","LU1282648689.USD","LU1831875114.USD","03143","LU0164865239.USD","00042","LU0244354667.USD","LU0269904917.USD","LU0315179316.USD","LU0588546209.SGD","HK0000352382.USD","LU0918141705.HKD","HK0000352291.HKD","HK0000165453.HKD","LU1105468828.SGD","LU2097828714.EUR","SG9999001093.SGD","SG9999012710.SGD","IE00B543WZ88.USD","LU0140636845.USD","BK1554","399300","LU0287142896.SGD","LU0509642566.USD","LU0648948544.HKD","LU0880133367.SGD","SG9999002950.SGD","01057","LU1366334651.USD","HK0000320223.HKD","LU0266512473.USD","SG9999001051.SGD","LU0886674414.USD","IE00B0169L03.USD","LU1655091616.SGD","IE0031814852.USD","BK1514","LU1993786604.SGD","LU2476274720.SGD","LU1807302812.USD","LU2543165471.USD","LU1794554557.SGD","LU1048596156.SGD","002202","LU0828237940.HKD","LU0918141887.USD","BK1584","HK0000306685.HKD","HK0000320264.USD","LU0593848301.USD","BK1544","BK1147","BK1592","LU0821914370.USD","LU0543330566.HKD","LU0871576103.HKD","BK1505","LU0314109678.HKD","LU0329678337.USD","LU0640798160.USD","LU0327786744.USD","LU0359202008.SGD","LU0456827905.SGD","BK1515","03750","LU0516423091.SGD","LU0797268264.HKD","LU1504937902.USD","LU2242644610.SGD","LU1960683339.HKD","LU0106252389.USD","BK1184","LU0348827113.USD","LU0531971595.HKD","BK1546","LU0828238088.HKD","BK1202","LU0516422952.EUR","LU2097828474.EUR","SG9999006597.SGD","LU1242518857.USD","BK1129","601628","LU0791591158.USD","BK1550","BK1163","LU0890818403.SGD","LU1328277881.USD","LU1224709979.USD","LU2226246903.HKD","IE00BF5LJ272.USD","LU1720050803.USD","LU0501845795.SGD","IE0034224299.USD","BK1105","LU1211504680.USD","SG9999002463.SGD","LU0823426480.USD","BK1509","LU0348814723.USD","LU1282649810.SGD","BK1130","BK1170","SG9999011746.SGD","LU1008478684.HKD","LU0181495838.USD","LU1152091168.USD","LU0096374516.USD","LU0502904849.HKD","LU0164880469.USD","LU0329678170.USD","LU1226287529.USD","BK1171","BK1198","LU1251922891.USD","LU0231483743.USD","LU1675838814.USD","LU1769817096.USD","LU2045819591.USD","BK1558","IE00BZ08YR35.GBP","000488","BK1594","IE00BZ08YT58.USD","LU0348735423.USD","LU0589944569.HKD","LU1152091754.HKD","LU0737861772.HKD","LU0163747925.USD","BK1564","LU1880383440.USD","LU0149721374.USD","LU0348805143.USD","LU0051755006.USD","02865","LU0307460666.USD","LU0348788117.USD","IE00B5MMRT66.SGD","BK1565","LU0345780281.USD","LU2778985437.USD","LU0463099449.HKD","IE00BGHQDM52.EUR","LU1303224171.USD","SG9999003461.SGD","LU1880383366.USD","LU1688375341.USD","LU0979878070.USD","LU0488056044.USD","LU0052750758.USD","LU0455707207.USD","LU0972618739.USD","BK1551","LU0228659784.USD"],"gpt_icon":1},{"id":"2604924221","title":"FIC/BIC管线突围、BD丰收、港股上市!2026，恒瑞医药站上“爆发点”","url":"https://stock-news.laohu8.com/highlight/detail?id=2604924221","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604924221?lang=zh_cn&edition=full","pubTime":"2026-01-18 11:25","pubTimestamp":1768706745,"startTime":"0","endTime":"0","summary":"GLP-1/GIP双激动剂HRS9531已在中国递交新药上市申请并获受理。自2023年以来，恒瑞已总计完成12笔对外授权交易，总价值超过270亿美元，其中累计获得13亿美元现金与股权注资。然而，恒瑞的国际化远不止于“借船出海”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU1023057109.AUD","LU1064130708.USD","LU1997245094.SGD","LU2488822045.USD","600276","LU1969619763.USD","LU2328871848.SGD","LU2148510915.USD","LU0359201612.USD","LU0359201885.HKD","BK0060","LU0405327148.USD","LU1781817850.SGD","LU2097828805.USD","LU2543165471.USD","LU2097828474.EUR","LU2289578879.USD","LU2097828714.EUR","LU2495084118.USD","BK1191","LU2580892862.HKD","LU0359202008.SGD","BK0028","BK0012","BK0239","LU2580892789.USD","LU1064131003.USD","BK0196","LU0405327494.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU1820825898.SGD","LU1328615791.USD","LU1255011170.USD","BK0183","LU1580142542.USD","LU1655091616.SGD","LU1997244956.HKD","01276","LU2097828557.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770040433499,"stockEarnings":[{"period":"1week","weight":-0.0141},{"period":"1month","weight":-0.0237},{"period":"3month","weight":-0.0934},{"period":"6month","weight":-0.0514},{"period":"1year","weight":0.3073},{"period":"ytd","weight":-0.0237}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0376},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.1567},{"period":"1year","weight":0.2668},{"period":"ytd","weight":0.0376}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"397246人(较上一季度增加8.94%)","perCapita":"16058股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}